ArticleCureus2025
Toxic Epidermal Necrolysis in an HIV-Infected Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal cutaneous adverse drug reactions, mediated by type IV hypersensitivity mechanisms triggered by medications such as antibiotics, antiepileptics, allopurinol, and non-steroidal anti-inflammatory drugs (NSAIDs). Various risk factors, including human immunodeficiency virus (HIV) infection, increase susceptibility to these severe reactions. Early symptoms are often non-specific and may precede the characteristic skin and mucosal lesions. Diagnosis requires thorough clinical and laboratory evaluation, including causality assessment tools such as the Algorithm for Drug Causality in Epidermal Necrolysis (ALDEN). Management demands a multidisciplinary approach focusing on supportive care and infection prevention, with emerging evidence supporting immunomodulatory therapies like cyclosporine and combined intravenous immunoglobulin and corticosteroids. This case report describes a 36-year-old HIV-positive man who developed carbamazepine-induced TEN. The diagnosis of TEN was confirmed clinically and supported by a positive causality assessment using the ALDEN. The patient was managed with supportive care and immunomodulatory treatment with cyclosporine and systemic corticosteroids, leading to gradual re-epithelialization and clinical improvement. This case highlights the increased risk of severe cutaneous adverse reactions in HIV-positive patients. Early recognition and multidisciplinary management are essential for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.